GSK pays Synta $15M in milestone fees for cancer drug

12/15/2008 | Boston Globe (tiered subscription model), The

Synta Pharmaceuticals got $15 million in milestone fees from GlaxoSmithKline in a collaboration to develop and market elesclomol, an experimental drug designed to destroy cancer cells. Under the deal, Synta is entitled to a total payment of $585 million for reaching clinical-testing goals or making regulatory submissions.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC